
Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Oliver Van Oekelen, MD, PhD is a bioinformatics-trained MD, PhD, working as an Internal Medicine Resident at the Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel hospital in New York City.

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

Published: September 24th 2025 | Updated: